EPICS Therapeutics
PrivateLast Round
VC Round
Sep 22, 2025
Total Funding Raised
$37.54M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
EPICS Therapeutics operates in Healthcare & Life Sciences and is based in Belgium. Its latest recorded funding round was a VC Round in September 2025.
EPICS Therapeutics is a biotechnology company that develops small molecule drugs targeting RNA epigenetic mechanisms for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EPICS Therapeutics Comparables
Compare EPICS Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| STORM Therapeutics | 91% | |
| Accent Therapeutics | 86% | |
| Rgenta Therapeutics | 79% |
For institutional investors. Book with your work email.
EPICS Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Sep 22, 2025 | ||||
| Series A Extension | Oct 18, 2024 | ||||
| Series A | Dec 21, 2018 | ||||
| Seed | May 24, 2018 |
For institutional investors. Book with your work email.
EPICS Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Federal Holding and Investment Company | VC Round, Series A, Series A Extension |
| Newton Biocapital | Series A, Seed, VC Round, Series A Extension |
| Fund+ | VC Round, Series A, Series A Extension |
| Société Régionale d'Investissement de Wallonie | Seed, Series A |
| Investsud | Seed |
| Wallonie Entreprendre | Seed, VC Round, Series A Extension |
| Theodorus | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors grew 43% MoM, reaching 720.
- Sep 22, 2025
Led by Newton Biocapital with participation from BNP Paribas.
For institutional investors. Book with your work email.
EPICS Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about EPICS Therapeutics's valuation, stock price, and market status.
Is EPICS Therapeutics a public or private company?
EPICS Therapeutics is a private company.
What is the current stock price of EPICS Therapeutics?
EPICS Therapeutics is a private company, so its shares have no public market price. Caplight tracks EPICS Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EPICS Therapeutics worth (valuation)?
Valuation information for EPICS Therapeutics is not publicly available.
Can I buy EPICS Therapeutics stock?
EPICS Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EPICS Therapeutics's last funding round?
EPICS Therapeutics's most recent funding round was VC Round on September 22, 2025.
Who are the main investors in EPICS Therapeutics?
Key investors in EPICS Therapeutics include Newton Biocapital.
Will EPICS Therapeutics IPO soon?
No public IPO plans have been announced for EPICS Therapeutics.
How can I track EPICS Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in EPICS Therapeutics's shares on secondary markets.